In-vitro/In-silico bio-equivalence trials as alternatives to clinical endpoint studies.
October 6, 2022 3:10 pmOn Friday October 7 at 2 PM EST, Jan De Backer CEO of Fluidda, will present at the RESCON-summit in New York. The presentation is entitled: “In-vitro/In-silico bio-equivalence trials as... View Article